1.77

9.26% 0.15

Pre-market: 1.76 -0.01 -0.56%

Engene Therapeutics Inc (ENGN)

Overview News Price History Financials Discussions Forecast

Engene Therapeutics Inc stock is traded at $1.77, with a volume of 2.15M. It is up +9.26% in the last 24 hours and up +2.91% over the past month. enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.

Previous Close:

$1.62

Open:

$1.75

24h Volume:

2.15M

Relative Volume:

1.40

Market Cap:

$118.57M

Revenue:

Net Income/Loss:

$-122.44M

P/E Ratio:

-0.7853

EPS:

-2.254

Net Cash Flow:

$-103.79M

1W Performance:

+7.27%

1M Performance:

+2.91%

6M Performance:

-79.00%

1Y Performance:

-46.85%

1-Day Range:

$1.73

$1.82

1-Week Range:

$1.57

$1.82

52-Week Range:

$1.40

$12.25

Engene Therapeutics Inc Stock (ENGN) Company Profile

Name

Engene Therapeutics Inc

Sector

Healthcare (1104)

Industry

Biotechnology (621)

Phone

(514) 332-4888

Address

4868 RUE LEVY, SUITE 220, SAINT-LAURENT

Employee

Twitter

Next Earnings Date

2026-06-11

Latest SEC Filings

ENGN's Discussions on Twitter

Compare ENGN vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ENGN Engene Therapeutics Inc	1.77	118.57M	0	-122.44M	-103.79M	-2.254
VRTX Vertex Pharmaceuticals Inc	450.46	114.33B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	614.98	64.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	884.20	54.99B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	287.80	38.42B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	160.06	34.03B	742.00K	-1.37B	-1.07B	-7.0731

Engene Therapeutics Inc Stock (ENGN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-13-26	Initiated	WBB Securities	Buy
Jan-30-26	Initiated	Jefferies	Buy
Nov-11-25	Upgrade	Raymond James	Outperform → Strong Buy
Feb-18-25	Initiated	Piper Sandler	Overweight
Feb-14-25	Downgrade	UBS	Buy → Neutral
Dec-23-24	Initiated	H.C. Wainwright	Buy
Nov-27-24	Initiated	Raymond James	Outperform
Nov-18-24	Initiated	JMP Securities	Mkt Outperform
Aug-28-24	Initiated	Oppenheimer	Outperform
Apr-22-24	Initiated	Wells Fargo	Overweight
Apr-15-24	Initiated	Guggenheim	Buy
Mar-28-24	Initiated	UBS	Buy
Mar-08-24	Initiated	Morgan Stanley	Overweight
Feb-20-24	Initiated	Leerink Partners	Outperform

View All

Engene Therapeutics Inc Stock (ENGN) Latest News

Jun 15, 2026

enGene Therapeutics Releases Q2 2026 Financial Results - AlphaStreet

Jun 15, 2026

EnGene Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2026 - marketscreener.com

Jun 15, 2026

enGene Reports Second Quarter 2026 Financial Results and Provides Business Update - BioSpace

Jun 15, 2026